

Methods for Improved Detection of Oxacillin Resistance in Coagulase-Negative Staphylococci: Results of a Multicenter Study

FRED C. TENOVER,^{1*} RONALD N. JONES,² JANA M. SWENSON,¹ BARBARA ZIMMER,³ SIGRID McALLISTER,¹
AND JAMES H. JORGENSEN⁴ FOR THE NCCLS STAPHYLOCOCCUS WORKING GROUP†

Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333¹; Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52240²; Dade MicroScan, West Sacramento, California 95616³; and Department of Pathology, The University of Texas Health Science Center, San Antonio, Texas 78284⁴

Received 12 April 1999/Returned for modification 26 July 1999/Accepted 1 September 1999

A multilaboratory study was undertaken to determine the accuracy of the current National Committee for Clinical Laboratory Standards (NCCLS) oxacillin breakpoints for broth microdilution and disk diffusion testing of coagulase-negative staphylococci (CoNS) by using a PCR assay for *mecA* as the reference method. Fifty well-characterized strains of CoNS were tested for oxacillin susceptibility by the NCCLS broth microdilution and disk diffusion procedures in 11 laboratories. In addition, organisms were inoculated onto a pair of commercially prepared oxacillin agar screen plates containing 6 µg of oxacillin per ml and 4% NaCl. The results of this study and of several other published reports suggest that, in order to reliably detect the presence of resistance mediated by *mecA*, the oxacillin MIC breakpoint for defining resistance in CoNS should be lowered from ≥4 to ≥0.5 µg/ml and the breakpoint for susceptibility should be lowered from ≤2 to ≤0.25 µg/ml. In addition, a single disk diffusion breakpoint of ≤17 mm for resistance and ≥18 mm for susceptibility is suggested. Due to the poor sensitivity of the oxacillin agar screen plate for predicting resistance in this study, this test can no longer be recommended for use with CoNS. The proposed interpretive criteria for testing CoNS have been adopted by the NCCLS.

The coagulase-negative staphylococci (CoNS) comprise a group of species frequently associated with both community-acquired and nosocomial bloodstream infections, particularly in patients with indwelling catheters or other medical devices (2, 9, 15, 22). Isolates from a variety of CoNS species, including *Staphylococcus epidermidis*, *S. hominis*, *S. haemolyticus*, *S. saprophyticus*, *S. simulans*, and *S. warneri* have been reported to harbor the *mecA* determinant, which encodes a modified penicillin binding protein (PBP2a) and is responsible for resistance to the penicillinase-resistant penicillins, such as dicloxacillin, methicillin, nafcillin, and oxacillin (6, 12, 18, 20). The presence of the *mecA* gene in a staphylococcal isolate is considered synonymous with oxacillin resistance (1, 4, 17, 19). Thus, genetic assays for *mecA* have often been used as the reference method for evaluating new methods of antimicrobial susceptibility testing for staphylococci (1, 3, 6, 10, 16, 23).

Many investigators have reported discrepancies between the results of *mecA* genetic assays and MIC tests for oxacillin resistance when the results of MIC testing were interpreted by using the current National Committee for Clinical Laboratory

Standards (NCCLS) breakpoints of ≤2 µg/ml for susceptibility and ≥4 µg/ml for resistance (3, 6, 9, 10, 13, 14, 17, 21). There are also conflicting data regarding the accuracy of the oxacillin agar screen test, in which an agar plate containing 6 µg of oxacillin per ml and 4% NaCl is inoculated with a heavy suspension of the staphylococcal test organism, compared to the results of a PCR assay for *mecA* (3, 8, 17, 23). More recently, the accuracy of the oxacillin disk diffusion test also has come into question (3, 6, 9, 23). However, none of the studies cited above were conducted in multiple laboratories, although strains from many institutions and geographic locations were sampled.

To determine the accuracy of the oxacillin broth microdilution, disk diffusion, and agar screen tests, we tested 50 well-characterized CoNS strains in 11 laboratories and compared those results to the results of a PCR assay for *mecA* performed in 3 laboratories. The goal of this study was to either validate the existing NCCLS breakpoints or modify the breakpoints to make them conform to the results of genotypic (*mecA*) testing.

MATERIALS AND METHODS

Bacterial strains and study format. Fifty strains of CoNS were selected from the strain collections at the Centers for Disease Control and Prevention (CDC), the University of California at San Francisco, and the University of Iowa College of Medicine. Isolates were frozen and distributed to 10 laboratories with previous experience in performing broth microdilution MIC and disk diffusion testing. The laboratories were Dade MicroScan, West Sacramento, Calif.; Duke University, Durham, N.C.; The Johns Hopkins Hospital, Baltimore, Md.; Northwestern Memorial Hospital, Chicago, Ill.; Ohio State University, Columbus; Robert Wood Johnson Medical School, New Brunswick, N.J.; University of California at San Francisco; University of Iowa, Iowa City; University of Texas Health Science Center at San Antonio; and Washington University School of Medicine, St. Louis, Mo. Testing was also performed at the Nosocomial Pathogens Laboratory Branch at CDC. All materials for the study were supplied to the laboratories except for the Mueller-Hinton agar plates for disk diffusion testing, which were purchased locally. All laboratories performed broth microdilution (14), disk diffusion (13), and the oxacillin agar screening test (13), using the methods

* Corresponding author. Mailing address: Nosocomial Pathogens Laboratory Branch (G08), Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30333. Phone: (404) 639-3246. Fax: (404) 639-1381. E-mail: fnt1@CDC.GOV.

† The other members of the NCCLS Staphylococcus Working Group are William J. Buesching and Robert J. Fass, Ohio State University Medical Center, Columbus; James D. Dick, The Johns Hopkins Hospital, Baltimore, Md.; Patrick R. Murray, Barnes-Jewish Hospital, St. Louis, Mo.; Lance R. Peterson, Northwestern Memorial Hospital, Chicago, Ill.; L. Barth Reller, Duke University Medical Center, Durham, N.C.; Melvin P. Weinstein, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J.; and Mary K. York, University of California, San Francisco.

described by NCCLS, on the same 50 test strains. Previous test results from an additional 200 isolates of CoNS from CDC (see below) were reanalyzed by using the new MIC and disk diffusion breakpoints.

Organisms tested. Most of the CoNS strains chosen for this study had previously demonstrated oxacillin MICs ranging from 0.25 to 4 µg/ml. The organisms were identified by standard biochemical methods (7). The distribution of species is as follows (with the total number of strains/number of *mecA* positive strains, given in parentheses after each species name): *S. epidermidis* (27/18), *S. hominis* (8/5), *S. warneri* (6/1), *S. haemolyticus* (3/3), *S. lugdunensis* (2/0), *S. saprophyticus* (2/1), *S. capitis* (1/0), and *S. simulans* (1/1). *S. aureus* ATCC 29213, ATCC 25923, and ATCC 43300 were included for quality control (13, 14). Each strain was subcultured to ensure purity and was frozen for distribution to the participating laboratories. Identification to species level and the presence or absence of *mecA* were verified or determined prior to shipment. The additional 200 isolates of CoNS included 141 isolates chosen from the CDC strain collection (total number/number *mecA* positive), i.e., *S. epidermidis* (48/43), *S. haemolyticus* (27/23), *S. hominis* (13/8), *S. lugdunensis* (9/0), *S. simulans* (8/4), *S. saprophyticus* (7/1), *S. warneri* (5/2), *S. intermedius* (5/1), *S. cohnii* (4/0), *S. xyloso* (3/0), *S. hyicus* (2/0), *S. auricularis* (2/0), *S. capitis* (1/0), *S. saccharolyticus* (1/0), and *Staphylococcus* species (5/1), and 59 fresh clinical isolates of CoNS from five laboratories around the United States, i.e., *S. epidermidis* (47/35), *S. hominis* (8/6), *S. capitis* (2/0), *S. warneri* (1/0), and *S. auricularis* (1/0). All 200 of these were tested previously at CDC with cation-adjusted Mueller-Hinton broth (CAMHB) by the NCCLS method.

Inoculum preparation. Inoculum for all tests was prepared from a blood agar plate that had been streaked with a single colony from an initial subculture plate and incubated for 18 to 24 h. The test inoculum was prepared by removing growth from the blood agar plate, inoculating it directly into Mueller-Hinton broth, and adjusting the inoculum to equal a 0.5 McFarland turbidity standard (14). The final inoculum for the broth microdilution tests was determined from both MIC plates for each organism by each laboratory by removing 20 µl from a growth control well, diluting it in 10 ml of saline just after inoculation, and, after mixing well, spreading 100 µl onto each of two blood agar plates.

Broth microdilution tests. Panels were prepared by two laboratories, CDC and Dade MicroScan, by following NCCLS reference procedures (13, 14). The panels contained oxacillin (range, 0.015 to 32 µg/ml), vancomycin (0.06 to 64 µg/ml), penicillin (0.12 to 128 µg/ml), and erythromycin (0.03 to 32 µg/ml). Vancomycin was obtained from Lilly Research Laboratories (Indianapolis, Ind.); penicillin, erythromycin, and oxacillin were obtained from Sigma (St. Louis, Mo.). (Data for drugs other than oxacillin are not reported here.) The panels were made using two different lots of CAMHB, i.e., a common lot of CAMHB (Difco Laboratories, Detroit, Mich.) used by both laboratories and one unique lot (from Acumedia, Westlake, Ohio, for CDC and from Becton Dickinson Microbiology Systems [BDMS], Cockeysville, Md., for MicroScan; the latter was specifically prepared for MicroScan panels). The CAMHB for oxacillin testing was supplemented with 2% NaCl. Inoculation was performed and final inoculum counts were determined on all MIC plates as described above. Panels were incubated at 35°C and read at 24 h to determine the oxacillin MICs. The significance of differences between the results of the MIC tests determined with the different lots of media was determined by the Wilcoxon signed rank test.

Disk diffusion tests. Each laboratory performed disk diffusion tests using locally obtained Mueller-Hinton agar. Seven laboratories used commercially prepared BDMS Mueller-Hinton agar, three laboratories used commercially prepared Remel (Lenexa, Kans.) Mueller-Hinton agar, and one laboratory prepared its plates in-house using BDMS agar. No common lot of medium was included. Oxacillin disks (1 µg; BDMS) were supplied to each laboratory for the study. Oxacillin zone diameters were measured after 24 h of incubation in ambient air at 35°C.

Oxacillin agar screen test. The oxacillin agar screen test was performed with agar plates from two commercial sources, Remel and BDMS. The plates were inoculated in two ways with a cotton swab dipped into the 0.5 McFarland suspension: (i) by leaving the swab wet, and (ii) after expressing the fluid, as would be done for disk diffusion testing. For both methods, the plates were inoculated by making a spot about the diameter of a dime (~15 mm) onto a quadrant of the plate. The plates were incubated in ambient air at 35°C and read at 24 and 48 h. Growth of >1 colony was interpreted as positive.

PCR for *mecA*. The PCR assays for *mecA* were performed at CDC as described by Murakami et al. (12). The assays were also performed at the University of Iowa College of Medicine and Massachusetts General Hospital by using in-house protocols.

RESULTS

Inoculum determinations. Each laboratory determined the inoculum density of each study organism by sampling one well of each MIC plate. The results from each laboratory for each species were averaged, and the mean results are shown in Table 1. Most of the viable organism counts (observed range, 3×10^4 to 1.2×10^6 CFU/ml) were below the recommended density of 5×10^5 CFU/ml (ideal range, 3×10^5 to 7×10^5

TABLE 1. Inoculum counts performed on a single well of a broth microdilution plate

Species (no. of strains)	Mean (10^5) CFU/ml (range) ^a on a:	
	CDC plate	MicroScan plate
<i>S. epidermidis</i> (27)	1.78 (1.1–3.5)	1.63 (0.6–3.6)
<i>S. hominis</i> (8)	0.89 (0.3–2.1)	0.92 (0.3–2.6)
<i>S. warneri</i> (6)	1.60 (0.6–2.6)	1.53 (0.6–3.6)
<i>S. haemolyticus</i> (3)	1.34 (0.6–2.2)	1.17 (0.2–2.7)
<i>S. lugdunensis</i> (2)	4.43 ^b (0.9–10.6)	4.14 ^b (0.9–12.1)
<i>S. saprophyticus</i> (2)	2.57 (0.8–4.1)	2.31 (0.7–5.1)
<i>S. capitis</i> (1)	2.92 (0.98–5.4)	2.58 (0.7–4.8)
<i>S. simulans</i> (1)	2.02 (0.5–3.5)	1.66 (0.2–3.2)

^a The means represent the average counts from both MIC plates for each organism for each species counted in each laboratory. Each range consists of the mean from the laboratory with the lowest average counts per species and the mean from the laboratory with the highest average counts per species.

^b Counts within allowable range for final inoculum in MIC plates.

CFU/ml). Only the *S. lugdunensis* isolates produced average CFU counts near the midpoint of the ideal range on both MIC panels.

The effect of the medium on MIC results. The concentrations of oxacillin required to inhibit the growth of the 50 study isolates of CoNS were determined in 11 laboratories using two different MIC panels. Each reference MIC panel (one prepared at CDC and the other prepared at MicroScan) contained a common lot of medium (Difco) and a unique lot (Acumedia or BDMS). The oxacillin MIC results for the *mecA*-negative *S. epidermidis* isolates were highly comparable regardless of the source of medium used, with $\geq 99\%$ of values within ± 1 log₂ dilution (Table 2). However, significant variations in MICs were noted when the results generated with the common lot of Difco broth prepared by CDC were compared to those generated with the Difco broth prepared by MicroScan for *mecA*-negative organisms other than *S. epidermidis* and for all *mecA*-positive organisms. Similar differences were noted when the MIC results with the CDC Difco broth were compared to the results with the CDC Acumedia broth, and when the results with the MicroScan Difco broth were compared to the results with the MicroScan BDMS broth (Table 2). When the MIC results for all organisms were pooled, the Wilcoxon signed rank test indicated that the MIC results generated with the MicroScan Difco broth were significantly lower than the results with the CDC Difco broth ($P < 0.0001$). Similarly, the MicroScan BDMS results were significantly lower than the MicroScan Difco results ($P < 0.03$). The overall results obtained with the CDC Difco broth and the CDC Acumedia broth were not significantly different ($P = 0.25$). All of the quality control results for oxacillin testing of *S. aureus* ATCC 29213 by all 11 laboratories were within the published control ranges on each day of testing.

New MIC breakpoints. After examining the interpretive errors for each potential set of breakpoints (Table 3), we selected the values of ≤ 0.25 µg/ml for susceptibility and ≥ 0.5 µg/ml for resistance, since they showed the lowest numbers of category errors with these data sets and with other data sets reported in the literature. The percent correct values observed for each broth medium by using the current and proposed oxacillin MIC breakpoints are shown in Table 4. For *mecA*-positive strains, any MIC result that was not ≥ 0.5 µg/ml (proposed breakpoint) or ≥ 4.0 µg/ml (current breakpoint) was considered an error. Conversely, for *mecA*-negative strains, any oxacillin MIC result of ≤ 0.25 µg/ml (proposed breakpoint) or ≤ 2.0 µg/ml (current breakpoint) was considered an error. The

TABLE 2. Effect of medium source on oxacillin MICs expressed as dilution difference of MICs

Organism group and media	No. of results with a dilution difference of:						% of results within a dilution difference of ± 1	
	≥ -3	-2	-1^a	0	$+1^b$	+2		$\geq +3$
<i>mecA</i> negative								
<i>S. epidermidis</i>								
CDC Difco vs. MicroScan Difco			5	76	16			100
CDC Difco vs. CDC Acumedia			13	77	9		1	99.0
MicroScan Difco vs. MicroScan BDMS		1	37	58	2			99.0
Other species								
CDC Difco vs. MicroScan Difco		8	32	71	18			93.8
CDC Difco vs. CDC Acumedia		19	38	54	6			83.8
MicroScan Difco vs. MicroScan BDMS		8	44	77	1			93.8
<i>mecA</i> positive								
<i>S. epidermidis</i>								
CDC Difco vs. MicroScan Difco	29	50	77	29	5	1		58.1
CDC Difco vs. CDC Acumedia	1	7	18	45	54	46	11	64.3
MicroScan Difco vs. MicroScan BDMS	2	3	12	45	91	33	11	75.1
Other species								
CDC Difco vs. MicroScan Difco	2	18	20	24	15	2		76.5
CDC Difco vs. CDC Acumedia	26	12	9	22	6			49.3
MicroScan Difco vs. MicroScan BDMS	1	6	21	39	12	3		87.8

^a The second parameter in the comparison is lower.

^b The second parameter in the comparison is higher.

oxacillin MICs of a large percentage of the *mecA*-positive strains were below the current NCCLS resistance breakpoint of ≥ 4.0 $\mu\text{g/ml}$ with all four media (Table 4). However, very few errors were obtained with *mecA*-negative strains by using the current breakpoints.

For the *mecA*-positive strains, most of the errors (i.e., those strains classified as susceptible by MIC testing) were limited to only a few strains. For example, all nine errors with the CDC Difco medium for *mecA*-positive *S. epidermidis* isolates resulted from problems with a single strain, *S. epidermidis* 42.

The major problem with the lower oxacillin breakpoints was the number of false-resistant results, i.e., *mecA*-negative strains classified as resistant by MIC testing. These were mainly CoNS other than *S. epidermidis* (Table 4). The errors represented difficulties in testing a variety of *mecA*-negative staphylococcal species, including *S. warneri*, *S. capitis*, *S. lugdunensis*, and *S. saprophyticus*, the oxacillin MICs for all these species tend to be higher than those for *mecA*-negative *S. epidermidis* strains. For these strains, the results of MIC testing were comparable among the 11 laboratories and were not skewed by the results of any single laboratory (data not shown).

Selection of disk diffusion breakpoints. The scattergrams showing the MIC results with MicroScan BDMS Mueller-Hinton broth versus the disk diffusion zone diameter measurements obtained in each of the 11 laboratories for the 50 CoNS

study isolates are shown in Fig. 1A (*mecA*-positive strains) and Fig. 1B (*mecA*-negative strains). The MicroScan BDMS broth values were selected for further analysis because they demonstrated the best correlation with the results of *mecA* testing (Table 3). By using the MIC breakpoints of ≤ 0.25 $\mu\text{g/ml}$ for susceptibility and ≥ 0.5 $\mu\text{g/ml}$ for resistance, disk diffusion breakpoints of ≤ 17 mm for resistance and ≥ 18 mm for susceptibility were chosen. Since the scattergram represents results of replicate testing of 50 isolates in 11 laboratories, true error rates cannot be calculated. However, of the 25 discordant results between MIC and disk diffusion testing in the upper right quadrants of Fig. 1 (those analogous to "very major errors") that were determined by using MIC results (not *mecA* results), 23 results were for *mecA*-positive strains, 15 of which were due to two *S. epidermidis* strains, one *S. simulans* strain, and two *S. hominis* strains. Conversely, the "major errors" (lower left quadrants) were primarily due to a single *mecA*-positive *S. epidermidis* strain (strain 42) and the same *S. hominis* strains that caused the very major errors.

Figure 1B (upper left quadrant) shows several *mecA*-negative isolates that are classified both by MIC testing and by disk diffusion testing as resistant. The 41 results represent replicate testing of only four strains, i.e., one *S. saprophyticus*, one *S. warneri*, and two *S. lugdunensis* strains. The six values in the

TABLE 3. Comparison of results with different reference plates and medium manufacturers by *mecA* and oxacillin MIC breakpoint

Plate/medium	No. (%) of results with the indicated MIC ($\mu\text{g/ml}$) for:							
	<i>mecA</i> -positive strains ($n = 318$)				<i>mecA</i> -negative strains ($n = 230$)			
	≥ 4	≥ 2	≥ 1	≥ 0.5	≤ 2	≤ 1	≤ 0.5	≤ 0.25
CDC/Difco	182 (57)	260 (82)	290 (91)	298 (94)	224 ^a (99)	211 (93)	195 (86)	166 ^a (73)
MicroScan/Difco	82 (26)	145 (46)	255 (80)	299 (94)	230 (100)	218 (95)	197 (86)	171 (74)
CDC/Acumedia	198 (62)	240 (76)	257 (81)	267 (84)	222 ^b (98)	216 (96)	202 (89)	175 ^b (77)
MicroScan/BDMS	143 (45)	209 (66)	272 (86)	297 (93)	230 (100)	227 (99)	211 (92)	186 (81)

^a $n = 227$. Differences were due to growth failures in some MIC plates.

^b $n = 226$. Differences were due to growth failures in some MIC plates.

TABLE 4. Correlation of *mecA* PCR test results with MIC category results for current and proposed oxacillin breakpoints

Organism group (no. of tests)	% Correct values with the indicated medium by MIC breakpoint ^a							
	Proposed ($\leq 0.25 = S$; $\geq 0.5 = R$)				Current ($\leq 2.0 = S$; $\geq 4.0 = R$)			
	CDC Difco	MScan Difco	CDC Acumedia	MScan BDMS	CDC Difco	MScan Difco	CDC Acumedia	MScan BDMS
<i>mecA</i> positive								
<i>S. epidermidis</i> (198)	95.5	96.0	94.4	93.4	52.5	8.1	72.3	40.9
Other species (120)	90.8	90.8	66.7	93.3	65.0	55.0	40.8	51.7
All strains	93.7	94.0	84.0	93.4	57.2	25.8	62.3	45.0
<i>mecA</i> negative								
<i>S. epidermidis</i> (99)	100 (97) ^b	100 (98)	99.0 (97)	100 (99)	100 (97)	100 (98)	100 (97)	100 (99)
Other species (132)	52.7 (129)	55.0 (131)	60.9 (126)	66.4 (131)	97.7 (129)	100 (131)	96.9 (126)	100 (131)
All strains	73.1	74.3	77.4	80.9	98.7	100	98.2	100

^a For *mecA*-positive strains, MICs must be ≥ 0.5 $\mu\text{g/ml}$ for proposed breakpoints or ≥ 4.0 $\mu\text{g/ml}$ for current breakpoints to be considered correct; for *mecA*-negative strains, MICs must be ≤ 0.25 $\mu\text{g/ml}$ for proposed breakpoints or ≤ 2.0 $\mu\text{g/ml}$ for current breakpoints to be considered correct. MScan, MicroScan; S, susceptible; R, resistant.

^b Number given in parentheses is the total number of results used for calculations. Differences were due to growth failures in some MIC plates.

lower left quadrant of Fig. 1B are also results for *S. warneri* and *S. lugdunensis* strains.

Since the isolates selected for this study were weighted towards organisms for which the oxacillin MICs are close to the current NCCLS breakpoint, the number of errors may be artificially high. To control for the potential impact of examining only organisms that were difficult to test, we applied the new MIC and disk diffusion breakpoints to a collection of CoNS isolates from five U.S. laboratories, tested over the last 5 years at CDC. Figure 2A (*mecA*-positive strains) and Fig. 2B (*mecA*-negative strains) show only two very major errors (one *mecA*-positive *S. simulans* strain and one *mecA*-negative *S. haemolyticus* strain) and one major error (one *mecA*-negative *S. auricularis* strain). However, 28 of 75 *mecA*-negative strains were classified as resistant by both the MIC and disk diffusion methods, including nine of nine *S. lugdunensis* strains, six of six *S. saprophyticus* strains, and *mecA*-negative strains of nine other staphylococcal species. None of the *mecA*-negative strains of *S. epidermidis* from the CDC data set were misclassified by using the proposed breakpoints.

Oxacillin agar screen test. The results of the oxacillin agar screen tests are shown in Table 5. As expected, the tests with plates that were inoculated with a wet swab (higher inoculum) showed greater sensitivity in detecting *mecA*-positive strains than did those in which the liquid had been expressed from the swab prior to inoculation of the plate. However, even after 48 h of incubation, both commercial tests demonstrated unacceptably low sensitivities for *mecA*-positive strains. The Remel screening medium showed the highest sensitivity at 48 h for *mecA*-positive *S. epidermidis* strains (81.3%).

DISCUSSION

Testing for oxacillin resistance in staphylococci has been a challenge for clinical laboratories for more than 15 years (11). Recently, several investigators have noted discrepancies between the results of MIC tests using the current NCCLS MIC breakpoint for oxacillin and the results of *mecA* assays (3, 9, 10, 17, 23). Based on these findings, they have suggested that the MIC susceptibility breakpoint for oxacillin should be lowered significantly below its current value of 2 $\mu\text{g/ml}$. However, the reasons for the poor correlation between MICs and the genetic assays used as the reference method were not enumerated in these reports. One of the goals of this study was to determine what factors may be responsible for the discrepancies between the phenotypic and genotypic results. In this regard, our data

suggest that the source of Mueller-Hinton broth is one of the key factors that influence the oxacillin MIC results. Although Hindler and Warner reported several years ago that the source of Mueller-Hinton agar affected the results of the oxacillin screen test (5), the source of Mueller-Hinton broth apparently has not been considered to be a cause of discrepancies with broth microdilution MIC results. However, it is clearly not the only factor, since even the same lot of Difco medium gave statistically different oxacillin MIC results in panels prepared separately by two laboratories. Extensive review of the way in which both panels were prepared failed to reveal any substantial differences that could explain the variance in results. Both panels were supplemented, sterilized, and shipped in similar fashions. Although the MicroScan plates had V-shaped wells and the CDC plates had U-shaped wells, we do not think this can account for the differences observed. While the differences in results remain unresolved, we can conclude that part of the problem in previous reports of differences between MICs and *mecA* tests is likely to be medium related.

A second factor that influences MIC results is inoculum size. This study demonstrated that despite following the standard guidelines recommended by NCCLS, most of the participating laboratories unintentionally used an inoculum below the target concentration of 5×10^5 CFU/ml. This low inoculum was observed during testing of *S. epidermidis* isolates and a variety of other staphylococcal species. Given a typically low inoculum, it is not surprising that laboratories experienced problems with testing oxacillin, since many of the isolates tested are known to be heteroresistant and the number of daughter cells expressing the resistant phenotype may be less than 1 in 100,000 (4). While adjusting the inoculum suspension to a 1.0 McFarland standard to raise the actual inoculum size to the desired range may have been a reasonable suggestion prior to altering the breakpoints, with the proposed breakpoints, such an adjustment would only further contribute to the problem of classifying *mecA*-negative strains as resistant.

The proposed MIC breakpoints for oxacillin are lower than those advocated previously by York et al. (≤ 1 $\mu\text{g/ml}$ for susceptibility) (23) and by Cormican et al. and McDonald et al. (both of whom proposed ≤ 0.5 $\mu\text{g/ml}$ for susceptibility) (3, 10) but are consistent with those proposed by Marshall et al. (9). In our study, data from all of the above reports were taken into consideration. The breakpoints chosen appear to be the best choice for maximizing the sensitivity of detection of *mecA*-positive *S. epidermidis* isolates without severely compromising




FIG. 1. Scatterplots of oxacillin MICs versus oxacillin disk diffusion zone diameters for 50 CoNS tested in 11 laboratories. Proposed MIC and disk diffusion breakpoints are indicated by horizontal and vertical lines, respectively. (A) *mecA*-positive strains; (B) *mecA*-negative strains.

specificity. This approach was taken because *S. epidermidis* is the major CoNS species tested by clinical laboratories (2, 9, 22). However, for CoNS other than *S. epidermidis*, the proposed breakpoints are less effective in differentiating *mecA*-

positive from *mecA*-negative strains (Table 4). Strains of several species for which the oxacillin MICs were 0.5 to 2.0 µg/ml were consistently *mecA* negative. Decreased susceptibility to oxacillin in these isolates may be due to alterations in penicillin




FIG. 2. Scatterplots of oxacillin MICs versus oxacillin disk diffusion zone diameters for 200 CoNS tested at CDC. Proposed MIC and disk diffusion breakpoints are indicated by horizontal and vertical lines, respectively. (A) *mecA*-positive strains; (B) *mecA*-negative strains.

binding proteins (PBPs) other than PBP2. For example, Suzuki et al. reported changes in PBPs 1 and 4 in several strains of methicillin-resistant, *mecA*-negative *S. haemolyticus* and *S. saprophyticus* (18). Whether strains of CoNS (other than *S. epi-*

dermidis) for which oxacillin MICs were in the range of 0.5 to 2.0 µg/ml would be eradicated with penicillinase-resistant penicillins remains an open question. Until clinical data clarifying the relationship of *mecA* results and the results of phenotypic

TABLE 5. Correlation of *mecA* PCR test results with results of the oxacillin agar screen test

Organism group (no. of test results)	% Correct results by oxacillin screen plate manufacturer and inoculation method ^a							
	Remel				BDMS			
	Wet		Expressed		Wet		Expressed	
	24 h	48 h	24 h	48 h	24 h	48 h	24 h	48 h
<i>S. epidermidis</i> , <i>mecA</i> -positive (198)	62.6	81.3	52.0	74.2	22.2	54.5	15.7	38.9
Other species, <i>mecA</i> -positive (120)	59.2	73.3	50.0	64.2	51.7	73.3	45.0	61.7
<i>S. epidermidis</i> , <i>mecA</i> -negative (99)	100	100	100	100	100	100	100	99.0
Other species, ^b <i>mecA</i> -negative (129)	98.5	97.7	99.2	99.2	100	100	100	100

^a Percent correct results observed for each medium (growth for *mecA*-positive strains; no growth for *mecA*-negative strains). Wet, liquid was not expressed from the swab prior to inoculation of the agar screen plate; expressed, liquid was expressed from the swab prior to inoculation of the agar screen plate.

^b Data from three strains were deleted due to testing problems at one site.

tests are available, laboratories may choose to use either the broth microdilution or the disk diffusion method for testing CoNS, since both produce comparable results.

This study is the first to examine the accuracy of the oxacillin agar screen plate as applied to CoNS in multiple laboratories. In contrast to some earlier reports (23), the test showed low sensitivity even when a larger inoculum was used (the wet swab) and the plate was incubated for 48 h. This observation suggests that use of the oxacillin agar screening method should be reserved exclusively for detecting *mecA*-positive *S. aureus*.

Having modified the oxacillin MIC breakpoints, we needed to adjust the disk diffusion breakpoints as well. York et al. reported discrepancies between the results of disk diffusion testing and *mecA* results, particularly with *S. saprophyticus* isolates (23). As noted above, in both the study data set and the CDC data set, several isolates of *S. lugdunensis* and *S. saprophyticus*, as well as strains of nine other staphylococcal species, were oxacillin resistant by both disk diffusion and MIC methods, yet consistently tested *mecA* negative. Thus, the phenotypic tests yielded consistent results but were discrepant from the genotypic results. While part of the problem may be a function of the challenge set of organisms selected for this study, which overrepresents staphylococci for which MICs are between 0.25 and 4.0 µg/ml and contains some rare phenotypes, the lack of correlation with the results of *mecA* testing for these species remains a concern. Although the proposed breakpoints functioned well when applied to the results published by others, the number of strains representing species other than *S. epidermidis* in those studies was small (3, 9).

In summary, the data presented here, in conjunction with data previously published by Marshall et al. (9) and others (3, 11, 23), prompted NCCLS to modify the oxacillin MIC breakpoints for testing CoNS to ≤0.25 µg/ml for susceptibility and ≥0.5 µg/ml for resistance. In addition, a single disk diffusion breakpoint of ≤17 mm for resistance and ≥18 mm for susceptibility was adopted. These breakpoints produce consistent results for MIC testing and disk diffusion testing but show disagreement with regard to some *mecA*-negative, non-*S. epidermidis* strains of staphylococci. Finally, due to its poor performance in this study, the oxacillin agar screen plate is no longer recommended by NCCLS for testing CoNS but is limited to testing *S. aureus* strains only.

ACKNOWLEDGMENTS

We thank George Killgore and Mary Jane Ferraro for confirming the *mecA* results of the 50 strains and Michael Pfaller and Gary Doern for careful reading of the manuscript.

REFERENCES

1. Archer, G. L., and E. Pennell. 1990. Detection of methicillin resistance in staphylococci by using a DNA probe. *Antimicrob. Agents Chemother.* **34**:1720-1724.
2. Cockerill, F. R., III, J. G. Hughes, E. A. Vetter, R. A. Mueller, A. L. Weaver, D. M. Ilstrup, J. E. Rosenblatt, and W. R. Wilson. 1997. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of an aerobic culture of blood. *Clin. Infect. Dis.* **24**:403-418.
3. Cormican, M. G., W. W. Wile, M. S. Barrett, M. A. Pfaller, and R. N. Jones. 1996. Phenotypic detection of *mecA*-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests. *Diagn. Microbiol. Infect. Dis.* **25**:107-112.
4. de Lancaster, H., A. M. S. Figueiredo, and A. Tomasz. 1993. Genetic control of population structure in heterogeneous strains of methicillin-resistant *Staphylococcus aureus*. *Eur. J. Clin. Microbiol. Infect. Dis.* **12**:13-18.
5. Hindler, J. A., and N. L. Warner. 1987. Effect of source of Mueller-Hinton agar on detection of oxacillin resistance in *Staphylococcus aureus* using a screening methodology. *J. Clin. Microbiol.* **25**:734-735.
6. Huang, M. B., T. E. Gay, C. N. Baker, S. N. Banerjee, and F. C. Tenover. 1993. Two percent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. *J. Clin. Microbiol.* **31**:2683-2688.
7. Kloos, W. E., and T. L. Bannerman. 1995. *Staphylococcus* and *Micrococcus*, p. 282-298. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Tenover (ed.), *Manual of clinical microbiology*, 6th ed. ASM Press, Washington, D.C.
8. MacKenzie, A. M. R., H. Richardson, R. Lannigan, and D. Wood. 1995. Evidence that the National Committee for Clinical Laboratory Standards disk test is less sensitive than the screen plate for detection of low-expression-class methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* **33**:1909-1911.
9. Marshall, S. A., W. W. Wilke, M. A. Pfaller, and R. N. Jones. 1998. *Staphylococcus aureus* and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (*mecA*) characterization of oxacillin resistance in the SCOPE Program. *Diagn. Microbiol. Infect. Dis.* **30**:205-214.
10. McDonald, C. L., W. E. Maher, and R. J. Fass. 1995. Revised interpretation of oxacillin MICs for *Staphylococcus epidermidis* based on *mecA* detection. *Antimicrob. Agents Chemother.* **39**:982-984.
11. McDougal, L. K., and C. Thornsberry. 1984. New recommendations for disk diffusion antimicrobial susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. *J. Clin. Microbiol.* **19**:482-488.
12. Murakami, K., W. Minamide, K. Wada, E. Nakamura, H. Teraoka, and S. Watanabe. 1991. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. *J. Clin. Microbiol.* **29**:2240-2244.
13. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests, 6th ed., vol. 17, no. 1. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17, no. 2. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. National Nosocomial Infections Surveillance System. 1996. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. *Am. J. Infect. Control* **24**:380-388.
16. Peterson, A. C., H. Miorner, and C. Kamme. 1996. Identification of *mecA*-related oxacillin resistance in staphylococci by the Etest and the broth microdilution method. *J. Antimicrob. Chemother.* **37**:445-456.

17. **Ramotar, K., M. Bobrowska, P. Jessamine, and B. Toye.** 1998. Detection of methicillin-resistance in coagulase-negative staphylococci. *Diagn. Microbiol. Infect. Dis.* **30**:267–273.
18. **Suzuki, E., K. Hiramatsu, and T. Yokota.** 1992. Survey of methicillin-resistant clinical strains of coagulase-negative staphylococci for *mecA* gene distribution. *Antimicrob. Agents Chemother.* **36**:429–434.
19. **Tenover, F. C., T. Popovic, and Ø. Olsvik.** 1995. Genetic methods for detecting antibacterial resistance genes, p. 1368–1378. In P. R. Murray, E. J. Baron, M. A. Tenover, and R. H. Tenover (ed.), *Manual of clinical microbiology*, 6th ed. ASM Press, Washington, D.C.
20. **Ubukata, K., R. Nonoguchi, M. D. Song, M. Matsuhashi, and M. Konno.** 1990. Homology of *mecA* gene in methicillin-resistant *Staphylococcus haemolyticus* and *Staphylococcus simulans* to that of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **34**:170–172.
21. **Wallet, F., M. Roussel-Devallez, and R. J. Courcol.** 1996. Choice of a routine method for detecting methicillin-resistance in staphylococci. *J. Antimicrob. Chemother.* **37**:901–909.
22. **Weinstein, M. P., M. L. Towns, S. M. Quartey, S. Mirrett, L. G. Reimer, G. Parmigiani, and L. B. Reller.** 1997. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. *Clin. Infect. Dis.* **24**:584–602.
23. **York, M. K., L. Gibbs, F. Chehab, and G. F. Brooks.** 1996. Comparison of PCR detection of *mecA* with standard susceptibility testing methods to determine methicillin resistance in coagulase-negative staphylococci. *J. Clin. Microbiol.* **34**:249–253.